patent.fyi
Applications  /  US 2026/0355108
United States Patent Application Publication

US 2026/0355108 A1

Published
Nov 12, 2026
Filed
Jul 14, 2026
Earliest date on the face
Jun 10, 2021
Classification
A61K 9/0043
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Acetate buffer for nasal liquid

What ifWhat if an acetic acid and sodium acetate buffer controlled the pH of a citrate-free aqueous epinephrine formulation?
Claim language“and a citrate”

The ratio of acetic acid to sodium acetate sets the pH, and their combined concentration sets the buffer capacity. A metered nasal pump dispenses the solution through a spray nozzle.

1.1Citrate-free sealed dry powder

What ifWhat if a sealed epinephrine powder dose contained no citrate?
Claim language“and a citrate”

A sealed foil blister limits moisture uptake during storage. At delivery, an air pulse disperses the powder into the nasal cavity, where nasal fluid dissolves deposited particles.

1.2Direct placement of dissolving film

What ifWhat if a dissolving film placed directly against the nasal mucosa released the dose?
Claim language“actuating the intranasal device”

A thin water-soluble cellulose film contains epinephrine and citrate dispersed through its matrix. Nasal fluid hydrates the film and releases the dissolved ingredients at the contact surface.

1.2Gravity-fed nasal drops

What ifWhat if gravity transferred a premeasured liquid dose from an open cup into the nasal cavity?
Claim language“actuating the intranasal device”

A shallow cup with a fixed pouring lip holds the liquid dose. Tilting the cup directs the solution over the lip and into the nostril.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Nasal delivery in a veterinary laboratory

A veterinary bench fixture holds a cast model of a canine nasal cavity with a removable collection liner. A cradle seats a unit-dose device containing epinephrine and a citrate and aligns its nozzle with the model nostril. A mechanical lever actuates the device, and a rinse of the liner provides a sample for measuring epinephrine deposition.

Component substitution

Foil blister as the dose reservoir

A sealed aluminum laminate blister replaces a rigid dose reservoir and contains a unit dose of epinephrine and a citrate. The blister seats between a hand-compressed bellows and the nasal nozzle. The first part of the actuator stroke pierces the blister at its inlet and outlet, and the rest of the stroke drives air through the blister to carry the powder into the nasal cavity.

Parameter or scale variation

Adjustable angles for nasal deposition testing

A bench fixture holds a nasal cavity replica and a unit-dose device containing epinephrine and a citrate. A pivot through the replica nostril positions the nozzle at 0, 15, or 30 degrees relative to the fixture horizontal while a collar maintains a 5 mm insertion depth. The operator actuates a fresh device at each setting and collects powder from the replica for deposition measurements.

Combination with existing systems

Dose carriage inside an emergency cabinet

A wall-mounted emergency supply cabinet holds individually pouched intranasal devices in spring-fed slots. Each device contains a unit dose of epinephrine and a citrate, and a front gate releases one pouch when the cabinet handle is pulled. A door switch records cabinet opening, and the user removes the device from its pouch and actuates it at the nostril.

Automated or data-driven variant

Optical logging of powder discharge

An infrared emitter and photodiode face each other across opposed windows in the outlet channel of a unit-dose nasal device containing epinephrine and a citrate. A switch at the end of the actuator stroke triggers a controller to sample the photodiode signal. The controller logs the stroke and the transient drop in transmitted light as separate events, while the powder continues through the nozzle into the nasal cavity.

Gravimetric sorting of filled dose cartridges

An indexed conveyor carries dose cartridges through tare weighing, powder filling, gross weighing, and sealing stations. A controller associates both weights with the same conveyor pocket and subtracts the tare from the gross weight to determine the fill mass of epinephrine and citrate powder. A pneumatic gate diverts cartridges outside the configured mass limits, and cartridges within the limits proceed to sealing and installation in intranasal devices.

Specific version of a part

Foil blister with powder dose

A formed foil cavity holds one premeasured powder dose and a heat-sealed foil lid closes it. The blister sits in the nasal device between an air inlet and the nozzle passage.

Citrate pair in aqueous solution

An aqueous epinephrine salt solution contains dissolved citric acid and sodium citrate. The ratio of the acid to its salt sets the solution pH.

Piston-driven powder discharge

Pressing a thumb button drives a piston through a sealed air chamber. The displaced air passes through the powder reservoir and carries particles out through the nasal tip.

Single-stroke liquid spray

A plunger moves through a fixed stroke and displaces the contents of a prefilled liquid chamber. The liquid enters tangential channels in a swirl nozzle and exits as a spray of droplets.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2019/0269781 A1
Published
Sep 5, 2019
Filed
May 22, 2019
Class
A61K 47/26
Document BUS 10,729,685 B2
Published
Aug 4, 2020
Filed
Sep 15, 2014
Class
A61K 31/485
Claim 1
Document A
Document B
1.1providing an intranasal device, wherein the intranasal device contains a dose of the pharmaceutical composition, wherein the pharmaceutical composition comprises: a first active ingredient, wherein the first active ingredient comprises epinephrine or a pharmaceutically acceptable salt thereof; and a citrate;
Also provided are devices adapted for nasal delivery of a pharmaceutical formulation to a patient, including single, bi- and multidose delivery comprising a therapeutically effective amount of epinephrine and pharmaceutically acceptable salts thereof.
A · US 2019/0269781 A1 · ¶ 81
1.2actuating the intranasal device to deliver the dose of the pharmaceutical composition into a nasal cavity.
Pharmaceutical formulations are applied directly to the nasal cavity using the devices described herein. In the case of a spray, this may be achieved for example by means of a metering atomizing spray pump, e.g. a single, bi-dose or multiuse spray device, with or without a propellant.
A · US 2019/0269781 A1 · ¶ 398
After intranasal administration, the following mean exposures (AUC0-t) are observed.
B · US 10,729,685 B2 · ¶ 53

An empty cell means only that no passage was reproduced there.

Statements in these documents
A need exists for needle-free and non-invasive methods of dosing epinephrine.
A · US 2019/0269781 A1 · ¶ 3
Disclosed herein are methods, pharmaceutical formulations of epinephrine and methods of use thereof in the treatment of conditions such as type-1 hypersensitivity reactions (systemic allergic reaction), asthma, and cardiac arrest.
A · US 2019/0269781 A1 · ¶ 4
There is a need in the art for pharmaceutical compositions which minimize the ability for abuse, and when administered properly, provide an adequate and effective amount of drug.
B · US 10,729,685 B2 · ¶ 3
It is an object of the present invention to provide a pharmaceutical composition that reduces the potential for improper administration drugs but which, when administered as directed through oral administration, is capable of delivering a therapeutically effective dose to a subject.
B · US 10,729,685 B2 · ¶ 4
Cite aspatent.fyi, US 2026/0355108 A1, claim 1, first published 2026-11-19T07:53:10-05:00, https://patent.fyi/US20260355108/, SHA-256 68134fdf152af35213764be46eb6acb253133cd4d197772349b2be41b90a008c
First published
Permanent addresshttps://patent.fyi/US20260355108/
Content fingerprint (SHA-256)68134fdf152af35213764be46eb6acb253133cd4d197772349b2be41b90a008c
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi